Abstract: Provided are methods of treating kidney disorders in a subject by administering an effective amount of VEGFR agonist, e.g., a Flt1 agonist to a subject. The agonists are composed of compositions comprising VEGFR agonists, e.g., VEGF, antibodies directed to Flt1, Flt1 ligands, Flt1 small molecule activators, or Flt1 selective agents in a pharmaceutically acceptable carrier for use in activating Flt1.

Abstract: The present invention provides methods for modulating angiogenesis and/or apoptosis comprising modulating the activity of at least one VEGF-modulated gene polypeptide. The invention also provides pharmaceutical compositions for modulating angiogenesis and apoptosis for the prevention or treatment of diseases associated with VEGF-modulated genes expression. The invention also provides diagnostic assays that use VEGF-modulated gene polynucleotides that hybridize with naturally occurring sequences encoding VEGF-modulated genes and antibodies that specifically bind to the protein. The invention also provides novel human and mouse arginine-rich proteins (ARPs) and nucleotide sequences. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding ARPs and for a method for producing the protein.

Abstract: Smart test attributes are objects that are arranged to incorporate attributes functionality in the attributes themselves and to provide a standard way to interact with the attributes through a set of interfaces. The set of interfaces includes interfaces for class level attributes, method level attributes, and parameter level attributes. Test class attributes can be used to modify an instantiated object state, skip test extraction from a class, or cause test extraction to be performed multiple times for a denoted type. Method level attributes are capable of modifying method parameters and method execution. In an embodiment, method level attributes include execution attributes and supplemental attributes. Parameter level attributes are optionally used to modify the parameter input to a method and/or to modify a state of an object (e.g., the context) after a method has executed.

Abstract: Provided are methods of treating kidney disorders in a subject by administering an effective amount of VEGFR agonist, e.g., a Flt1 agonist to a subject. The agonists are composed of compositions comprising VEGFR agonists, e.g., VEGF, antibodies directed to Flt1, Flt1 ligands, Flt1 small molecule activators, or Flt1 selective agents in a pharmaceutically acceptable carrier for use in activating Flt1.

Abstract: Methods for the treatment of cancer with combination therapies that include anti-VEGF antibodies are provided. Methods for diagnosing resistant tumors are also provided.

Abstract: Transgenic non-human animals and methods of producing non-human transgenic animals comprising within their genome a conditional targeted mutation in a VEGFR, e.g., VEGFR1 or VEGFR2, gene are provided along with methods and vectors used to produce such animals or cells.

Abstract: Test software on a test client dynamically locates necessary files by replacing indirect file references in test code with actual file paths. File paths are determined using one or more root paths couple with one or more test parameters being used as a portion of the actual file path. Multiple root paths may be provided in a prioritized list, such that if a file is not found in a first location, additional locations are checked. Test software on a test controller receives a command to perform a test run and queries a data store for test information. A message is assembled using query results and delivered to one or more test clients for execution.

Abstract: The present invention is directed to methods and means for making and using Angptl3 polypeptides. The invention specifically concerns the use of Angptl3 polypeptides in inducing liver regeneration and angiogenesis. Further methods include the use of Angptl3 polypeptides in the diagnosis and treatment of liver disease. Also provided herein are antibodies which bind to the polypeptides of the present invention.

Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naive libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.

Abstract: The present invention is directed to methods and means for making and using Angpt13 polypeptides. The invention specifically concerns the use of Angpt13 polypeptides in inducing liver regeneration and angiogenesis. Further methods include the use of Angpt13 polypeptides in the diagnosis and treatment of liver disease. Also provided herein are antibodies which bind to the polypeptides of the present invention.

Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.

Abstract: The invention provides methods and compositions useful for modulating vascular integrity.

Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.

Abstract: A test method executor is an object designed to execute a test method. The test method executor typically implements a simple state engine that is used to process the data presented by each smart test attribute. The test method executor invokes particular test methods in response to the processed data. The test method executor then condenses the results from all the attributes typically into a simple return value, which is designed to be interpreted by the test harness. The return value indicates, for example, whether the executed test method was a success, failure, or if the test method was “skipped.” Additionally, the test method executor is used to gather data about the method being invoked (such as the method name, which attributes are present, and the like.

Abstract: A test services provider is an object that is arranged to provide a standardized interface for calling test harness provided functionality. The test services provider is not tied to a specific test harness, and provides a standard interface such that both test harness functionality and test cases can be written without beforehand knowledge of the other. In operation, the test harness registers the test services that provides with the test service provider, and the test cases retrieve the registered test services from the test harness as needed. Accordingly, the test case does not have to query the test harness itself for the object that provides the desired test harness functionality, but rather uses a standardized interface provided by the test services provider to retrieve the desired test services.

Abstract: The present invention is directed towards a test case inheritance behavior that can be controlled via attributes. A base test class from which test objects are derived are useful for reducing test case code and management. For example, base test classes and their derived objects can be used to implement steps that are common between the entire set of classes (e.g., launching a piece of software to be tested and getting it to a certain stage). The principle of inheritance simplifies management of the test software when, for example, the base class is modified, all of the tests which derive from that test case automatically are modified. Accordingly, only one item needs to be modified (instead of every tests) when a change is necessary to modify the way the software launches.

Abstract: The interrogation device is used for identifying a target device. A transmitter is designed for transmitting a coded electromagnetic radiation. The target device has sensor means for detecting this radiation and for converting it into electrical signals, which are supplied to an evaluation unit, as well as transmitting means which, in accordance with decisions made by the evaluation unit, return messages to receiving means located inside or outside of the transmitter. The transmitter comprises a circuit with an oscillator and an antenna, which are designed to generate individual pulses, or short bursts of pulses in the giga-frequency range, which are chronologically modulated. A coded information signal is obtained from these pulses.

Abstract: The present invention provides methods for modulating angiogenesis and/or apoptosis comprising modulating the activity of at least one VEGF-modulated gene polypeptide. The invention also provides pharmaceutical compositions for modulating angiogenesis and apoptosis for the prevention or treatment of diseases associated with VEGF-modulated genes expression. The invention also provides diagnostic assays that use VEGF-modulated gene polynucleotides that hybridize with naturally occurring sequences encoding VEGF-modulated genes and antibodies that specifically bind to the protein.

Abstract: Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy.

Abstract: The present invention is directed to methods and means for making and using Angptl3 polypeptides. The invention specifically concerns the use of Angptl3 polypeptides in inducing liver regeneration and angiogenesis. Further methods include the use of Angptl3 polypeptides in the diagnosis and treatment of liver disease. Also provided herein are antibodies which bind to the polypeptides of the present invention.